Literature DB >> 31366526

Chronic Myeloid Leukemia as Secondary Malignancy Following the Treatment of Hodgkin Lymphoma: A Case Series.

Ralph Millett1, Anita Aggarwal2, Imad Tabbara1,3, Samah Nassereddine4,3.   

Abstract

Secondary malignancies are relatively common and clinically important phenomena following both chemotherapy and radiotherapy. The majority of these cases are acute leukemias, the occurrence of which have been thoroughly documented and studied. More rarely, chronic myeloid leukemias (CML) may arise subsequent to treatment of a primary malignancy. Literature review on such developments following treatment of Hodgkin's Lymphoma (HL) is scant. Herein, the authors present three cases of CML diagnosed within five years of treatment initiation for Hodgkin's Lymphoma (HL); one of the three patients had CML with atypical variant carrying a rare mutation with BCR-JAK2 fusion. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  CML; Hodgkin lymphoma; secondary malignancy

Mesh:

Substances:

Year:  2019        PMID: 31366526     DOI: 10.21873/anticanres.13600

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  A Case of Preleukemic Chronic Myeloid Leukemia Following Chemotherapy and Autologous Transplantation for T-lymphoblastic Lymphoma.

Authors:  Hyunji Choi; Sung Ran Cho; Dahae Yang; Woonhyoung Lee; Hyunyong Hwang; Ho Sup Lee; Da Jung Kim; Taeyun Kim; Mi Hyang Kim
Journal:  Ann Lab Med       Date:  2020-09       Impact factor: 3.464

2.  Hodgkin Lymphoma as a Secondary Neoplasm During Therapy for Chronic Myeloid Leukaemia: Case Report and Review of the Literature.

Authors:  Edyta Paczkowska; Michał Janowski; Katarzyna Karpińska; Małgorzata Ryłów; Barbara Zdziarska; Wojciech Poncyljusz; Bogusław Machaliński
Journal:  Onco Targets Ther       Date:  2021-04-12       Impact factor: 4.147

3.  Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected.

Authors:  Liana E Gynn; Elizabeth Anderson; Gareth Robinson; Sarah A Wexler; Gillian Upstill-Goddard; Christine Cox; Jennifer E May
Journal:  Mutagenesis       Date:  2021-11-29       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.